Systemic Treatment Maturity Level: 0 Draft

Diagnosis reference in case the treatment was done for baseline

EpisodeEvent element containing the data regarding the patient's cancer

In which hospital was the SystemicTreatment performed

Select the type of systemic treatment administered. It is possible to directly select the single treatment as appropriate.

Chemotherapy - 4273629 Immunotherapy - 40310107 Targeted therapy - 912065

Clarifies the reasons why systemic therapy is administered • Curative chemotherapy is chemotherapy administered with the goal of achieving a complete remission and preventing the recurrence of cancer. • Palliative chemotherapy refers to any chemotherapy administration that is not curative but administered simply to decrease tumor load and increase life expectancy. It has been defined also as “…treatment in circumstances where the impact of intervention is insufficient to result in major survival advantage, but does affect improvement in terms of tumor‐related symptoms…”

Palliative - 4179711 Curative procedure intent - 4162591

Clarifies the context / how the therapy was administered alone or in conjunction with other treatments • Neoadjuvant: treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. • Adjuvant: additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. • Concomitant/concurrent: A treatment that is given at the same time as another (es. Chemotherapy and radiotherapy).

Neo-adjuvant - 44808409 Concomitant - 2000100028 Adjuvant - 44804498 Systemic treatment alone - 2000100029

Information for chemotherapy

Preoperative - 4119031 Postoperative period - 4118656 Hyperthermic intraperitoneal chemotherapy - 3184898 Therapeutic - 4133895

Specifies when systemic treatment begins

Specifies when systemic treatment ends

Clarifies how many times the treatment was administered. A cycle of treatment is a period of treatment followed by a period of rest (no treatment). For example, treatment given for one week followed by three weeks of rest is one cycle of treatment. A cycle can be repeated multiple times.

The regimen applied to the patient. If this is not present, or the specific regimen is not listed here, use the DrugsForTreatments entity.

Doxorubicin and Ifosfamide - 35806965 Ifosfamide and Paclitaxel - 35805248 doxorubicin and vincristine - 2000100054 Epirubicin monotherapy - 35804228 Etoposide monotherapy - 35803691 Gemcitabine monotherapy - 35804135 Ifosfamide and Gemcitabine - 35806435 gemcitabine and vincristine - 2000100055 high dose cisplatin - 2000100056 Ifosfamide monotherapy - 35804542 ifosfamide and etoposide - 2000100057 Irinotecan liposomal monotherapy - 35805368 Lenvatinib monotherapy - 35805795 Methotrexate monotherapy - 35804095 Nivolumab monotherapy - 35803677 ADT (other androgen deprivation therapy) - 35806821 Oxaliplatin monotherapy - 35805078 Paclitaxel monotherapy - 35804166 Gemcitabine and Paclitaxel - 35804158 Ifosfamide and Paclitaxel - 35805248 Paclitaxel and Trastuzumab (TH) - 35804201 Paclitaxel and Vinorelbine - 35101452 Pembrolizumab monotherapy - 35803678 Sorafenib monotherapy - 35803487 Trastuzumab emtansine monotherapy (TDM1) - 35805230 Trastuzumab monotherapy - 35804222 Vinorelbine monotherapy - 35804241 weekly carboplatin - 2000100058 weekly cisplatin - 2000100059

Epirubicin and Ifosfamide - 35806948 Vincristine and Doxorubicin and Ifosfamide - 2000100060 Vincristine, Actinomycin D, Ifosfamide ( VAI) - 35805452 Docetaxel and Gemcitabine - 35803577 Dacarbazine and Doxorubicin - 35806964 Methotrexate and Doxorubicin and Cisplatin - 2000100061 Methotrexate and Doxorubicin and Ifosfamide - 2000100062 Doxorubicin and Cisplatin and Ifosfamide - 2000100063 Cisplatin and Doxorubicin - 35804819 Methotrexate and Vinorelbine - 2000100064 Ifosfamide and Etoposide (IE) - 35805454 Vincristine and Doxorubicin and Cyclophosphamide - 2000100065 Cyclophosphamide and Etoposide - 35806476 Doxorubicin and Ifosfamide and Dacarbazine - 2000100066 Dacarbazine and Gemcitabine - 35806969 Cyclophosphamide and Topotecan - 35805453 Irinotecan and Vincristine - 2000100067 Irinotecan and Temozolomide - 35805455 Busulfan and Melphalan - 35804000 TNF and Melphalan - 2000100068 Cyclophosphamide and Vinorelbine - 2000100069 Vincristine, Ifosfamide, Doxorubicin, Etoposide (VIDE) - 35805451 Pazopanib monotherapy - 35805690 Regorafenib monotherapy - 35804569 high dose Ifosfamide - 2000100070

Specifies when the new systemic treatment begins, if a combination please specify the start of the first drug

Specifies when the new systemic treatment ends,if a combination please specify the end of the last drug

Clarifies the reasons why the treatment ended or was interrupted

Completed successfully - 44788181 Chemotherapy changed acute chemotherapy toxicity - 4162594 Treatment ended due to comorbidity - 2000100030 Intolerance to drug - 4240582 Procedure discontinued by patient - 37017062 Death - 4306655

Measures how well a cancer patient responds to treatment. RECIST criteria should not be applied. The definition of Complete response; Partial response; Stable disease; Progression, should be based on the clinical judgement based on imaging. Only when setting=neoadiuvant or palliative

Complete Remission - 32946 Partial Remission - 32947 Stable Disease - 32948 Progression - 32949 Not applicable - 4294169 (Not usable in OMOP)

Systemic Treatment Maturity Level: 0 Draft

Diagnosis reference in case the treatment was done for baseline

EpisodeEvent element containing the data regarding the patient's cancer

In which hospital was the SystemicTreatment performed

Select the type of systemic treatment administered. It is possible to directly select the single treatment as appropriate.

Chemotherapy - 4273629 Immunotherapy - 40310107 Targeted therapy - 912065

Clarifies the reasons why systemic therapy is administered • Curative chemotherapy is chemotherapy administered with the goal of achieving a complete remission and preventing the recurrence of cancer. • Palliative chemotherapy refers to any chemotherapy administration that is not curative but administered simply to decrease tumor load and increase life expectancy. It has been defined also as “…treatment in circumstances where the impact of intervention is insufficient to result in major survival advantage, but does affect improvement in terms of tumor‐related symptoms…”

Palliative - 4179711 Curative procedure intent - 4162591

Clarifies the context / how the therapy was administered alone or in conjunction with other treatments • Neoadjuvant: treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. • Adjuvant: additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. • Concomitant/concurrent: A treatment that is given at the same time as another (es. Chemotherapy and radiotherapy).

Neo-adjuvant - 44808409 Concomitant - 2000100028 Adjuvant - 44804498 Systemic treatment alone - 2000100029

Information for chemotherapy

Preoperative - 4119031 Postoperative period - 4118656 Hyperthermic intraperitoneal chemotherapy - 3184898 Therapeutic - 4133895

Specifies when systemic treatment begins

Specifies when systemic treatment ends

Clarifies how many times the treatment was administered. A cycle of treatment is a period of treatment followed by a period of rest (no treatment). For example, treatment given for one week followed by three weeks of rest is one cycle of treatment. A cycle can be repeated multiple times.

The regimen applied to the patient. If this is not present, or the specific regimen is not listed here, use the DrugsForTreatments entity.

Doxorubicin and Ifosfamide - 35806965 Ifosfamide and Paclitaxel - 35805248 doxorubicin and vincristine - 2000100054 Epirubicin monotherapy - 35804228 Etoposide monotherapy - 35803691 Gemcitabine monotherapy - 35804135 Ifosfamide and Gemcitabine - 35806435 gemcitabine and vincristine - 2000100055 high dose cisplatin - 2000100056 Ifosfamide monotherapy - 35804542 ifosfamide and etoposide - 2000100057 Irinotecan liposomal monotherapy - 35805368 Lenvatinib monotherapy - 35805795 Methotrexate monotherapy - 35804095 Nivolumab monotherapy - 35803677 ADT (other androgen deprivation therapy) - 35806821 Oxaliplatin monotherapy - 35805078 Paclitaxel monotherapy - 35804166 Gemcitabine and Paclitaxel - 35804158 Ifosfamide and Paclitaxel - 35805248 Paclitaxel and Trastuzumab (TH) - 35804201 Paclitaxel and Vinorelbine - 35101452 Pembrolizumab monotherapy - 35803678 Sorafenib monotherapy - 35803487 Trastuzumab emtansine monotherapy (TDM1) - 35805230 Trastuzumab monotherapy - 35804222 Vinorelbine monotherapy - 35804241 weekly carboplatin - 2000100058 weekly cisplatin - 2000100059

Epirubicin and Ifosfamide - 35806948 Vincristine and Doxorubicin and Ifosfamide - 2000100060 Vincristine, Actinomycin D, Ifosfamide ( VAI) - 35805452 Docetaxel and Gemcitabine - 35803577 Dacarbazine and Doxorubicin - 35806964 Methotrexate and Doxorubicin and Cisplatin - 2000100061 Methotrexate and Doxorubicin and Ifosfamide - 2000100062 Doxorubicin and Cisplatin and Ifosfamide - 2000100063 Cisplatin and Doxorubicin - 35804819 Methotrexate and Vinorelbine - 2000100064 Ifosfamide and Etoposide (IE) - 35805454 Vincristine and Doxorubicin and Cyclophosphamide - 2000100065 Cyclophosphamide and Etoposide - 35806476 Doxorubicin and Ifosfamide and Dacarbazine - 2000100066 Dacarbazine and Gemcitabine - 35806969 Cyclophosphamide and Topotecan - 35805453 Irinotecan and Vincristine - 2000100067 Irinotecan and Temozolomide - 35805455 Busulfan and Melphalan - 35804000 TNF and Melphalan - 2000100068 Cyclophosphamide and Vinorelbine - 2000100069 Vincristine, Ifosfamide, Doxorubicin, Etoposide (VIDE) - 35805451 Pazopanib monotherapy - 35805690 Regorafenib monotherapy - 35804569 high dose Ifosfamide - 2000100070

Specifies when the new systemic treatment begins, if a combination please specify the start of the first drug

Specifies when the new systemic treatment ends,if a combination please specify the end of the last drug

Clarifies the reasons why the treatment ended or was interrupted

Completed successfully - 44788181 Chemotherapy changed acute chemotherapy toxicity - 4162594 Treatment ended due to comorbidity - 2000100030 Intolerance to drug - 4240582 Procedure discontinued by patient - 37017062 Death - 4306655

Measures how well a cancer patient responds to treatment. RECIST criteria should not be applied. The definition of Complete response; Partial response; Stable disease; Progression, should be based on the clinical judgement based on imaging. Only when setting=neoadiuvant or palliative

Complete Remission - 32946 Partial Remission - 32947 Stable Disease - 32948 Progression - 32949 Not applicable - 4294169 (Not usable in OMOP)

Systemic Treatment Maturity Level: 0 Draft

Diagnosis reference in case the treatment was done for baseline

EpisodeEvent element containing the data regarding the patient's cancer

In which hospital was the SystemicTreatment performed

Select the type of systemic treatment administered. It is possible to directly select the single treatment as appropriate.

Chemotherapy - 4273629 Immunotherapy - 40310107 Targeted therapy - 912065

Clarifies the reasons why systemic therapy is administered • Curative chemotherapy is chemotherapy administered with the goal of achieving a complete remission and preventing the recurrence of cancer. • Palliative chemotherapy refers to any chemotherapy administration that is not curative but administered simply to decrease tumor load and increase life expectancy. It has been defined also as “…treatment in circumstances where the impact of intervention is insufficient to result in major survival advantage, but does affect improvement in terms of tumor‐related symptoms…”

Palliative - 4179711 Curative procedure intent - 4162591

Clarifies the context / how the therapy was administered alone or in conjunction with other treatments • Neoadjuvant: treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. • Adjuvant: additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. • Concomitant/concurrent: A treatment that is given at the same time as another (es. Chemotherapy and radiotherapy).

Neo-adjuvant - 44808409 Concomitant - 2000100028 Adjuvant - 44804498 Systemic treatment alone - 2000100029

Information for chemotherapy

Preoperative - 4119031 Postoperative period - 4118656 Hyperthermic intraperitoneal chemotherapy - 3184898 Therapeutic - 4133895

Specifies when systemic treatment begins

Specifies when systemic treatment ends

Clarifies how many times the treatment was administered. A cycle of treatment is a period of treatment followed by a period of rest (no treatment). For example, treatment given for one week followed by three weeks of rest is one cycle of treatment. A cycle can be repeated multiple times.

The regimen applied to the patient. If this is not present, or the specific regimen is not listed here, use the DrugsForTreatments entity.

Doxorubicin and Ifosfamide - 35806965 Ifosfamide and Paclitaxel - 35805248 doxorubicin and vincristine - 2000100054 Epirubicin monotherapy - 35804228 Etoposide monotherapy - 35803691 Gemcitabine monotherapy - 35804135 Ifosfamide and Gemcitabine - 35806435 gemcitabine and vincristine - 2000100055 high dose cisplatin - 2000100056 Ifosfamide monotherapy - 35804542 ifosfamide and etoposide - 2000100057 Irinotecan liposomal monotherapy - 35805368 Lenvatinib monotherapy - 35805795 Methotrexate monotherapy - 35804095 Nivolumab monotherapy - 35803677 ADT (other androgen deprivation therapy) - 35806821 Oxaliplatin monotherapy - 35805078 Paclitaxel monotherapy - 35804166 Gemcitabine and Paclitaxel - 35804158 Ifosfamide and Paclitaxel - 35805248 Paclitaxel and Trastuzumab (TH) - 35804201 Paclitaxel and Vinorelbine - 35101452 Pembrolizumab monotherapy - 35803678 Sorafenib monotherapy - 35803487 Trastuzumab emtansine monotherapy (TDM1) - 35805230 Trastuzumab monotherapy - 35804222 Vinorelbine monotherapy - 35804241 weekly carboplatin - 2000100058 weekly cisplatin - 2000100059

Epirubicin and Ifosfamide - 35806948 Vincristine and Doxorubicin and Ifosfamide - 2000100060 Vincristine, Actinomycin D, Ifosfamide ( VAI) - 35805452 Docetaxel and Gemcitabine - 35803577 Dacarbazine and Doxorubicin - 35806964 Methotrexate and Doxorubicin and Cisplatin - 2000100061 Methotrexate and Doxorubicin and Ifosfamide - 2000100062 Doxorubicin and Cisplatin and Ifosfamide - 2000100063 Cisplatin and Doxorubicin - 35804819 Methotrexate and Vinorelbine - 2000100064 Ifosfamide and Etoposide (IE) - 35805454 Vincristine and Doxorubicin and Cyclophosphamide - 2000100065 Cyclophosphamide and Etoposide - 35806476 Doxorubicin and Ifosfamide and Dacarbazine - 2000100066 Dacarbazine and Gemcitabine - 35806969 Cyclophosphamide and Topotecan - 35805453 Irinotecan and Vincristine - 2000100067 Irinotecan and Temozolomide - 35805455 Busulfan and Melphalan - 35804000 TNF and Melphalan - 2000100068 Cyclophosphamide and Vinorelbine - 2000100069 Vincristine, Ifosfamide, Doxorubicin, Etoposide (VIDE) - 35805451 Pazopanib monotherapy - 35805690 Regorafenib monotherapy - 35804569 high dose Ifosfamide - 2000100070

Specifies when the new systemic treatment begins, if a combination please specify the start of the first drug

Specifies when the new systemic treatment ends,if a combination please specify the end of the last drug

Clarifies the reasons why the treatment ended or was interrupted

Completed successfully - 44788181 Chemotherapy changed acute chemotherapy toxicity - 4162594 Treatment ended due to comorbidity - 2000100030 Intolerance to drug - 4240582 Procedure discontinued by patient - 37017062 Death - 4306655

Measures how well a cancer patient responds to treatment. RECIST criteria should not be applied. The definition of Complete response; Partial response; Stable disease; Progression, should be based on the clinical judgement based on imaging. Only when setting=neoadiuvant or palliative

Complete Remission - 32946 Partial Remission - 32947 Stable Disease - 32948 Progression - 32949 Not applicable - 4294169 (Not usable in OMOP)